Cytori Therapeutics Inc (NASDAQ:CYTX) announced that enrollment has been completed in its US Phase IIb Osteoarthritis trial. The ACT-OA trial is a double-blind randomized, …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that preclinical and mechanistic data from its thermal injury study, performed with support from the Biomedical Advanced Research and …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced the pricing of a registered direct public offering of Units, with each Unit consisting of one share of …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced today preliminary 12 month follow-up data from the 12 patient investigator initiated Scleradec-I clinical trial conducted by Prof. …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has designated …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that its exclusive licensee, Lorem Vascular, has been granted regulatory clearance for the Cytori Celution® System by the State Food and …
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it will formally launch and showcase its new Celase® GMP enzyme at the 2015 International Society for …
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) issued a positive opinion toward Cytori’s …
In a research report released Friday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Cytori Therapeutics (NASDAQ:CYTX) with a $6.00 price …
Roth Capital analyst Joseph Pantginis is out with a research report on Cytori Therapeutics (NASDAQ:CYTX) reiterating a Buy rating and a $3.50 price target, which …
